Q4 2024 Exagen Inc Earnings Call Transcript
Key Points
- Exagen Inc (XGN) achieved record total revenue of $55.6 million in 2024, driven by improvements in reimbursement.
- The company successfully launched new biomarkers for AVISE CTD, enhancing its product offering and clinical utility.
- Gross margins expanded by over 300 basis points in 2024, nearing the 60% mark, due to increased ASP and operational efficiency.
- Exagen Inc (XGN) reduced its adjusted EBITDA loss to approximately $10 million, showcasing a focus on prudent business operations.
- The company plans to expand its sales territories in 2025, indicating confidence in further growth and market penetration.
- Testing volume in 2024 did not meet expectations, with a decline of 11% compared to 2023.
- The company experienced a 4.5% reduction in its unique ordering physician base year-over-year.
- There is uncertainty regarding the full financial impact of the new biomarkers, with precise ASP and revenue effects still being determined.
- Exagen Inc (XGN) faced challenges with some physicians unable to support necessary documentation for reimbursement, impacting volume.
- The company is still working on optimizing processes to reduce friction in prior authorization and medical record requests.
Greetings and welcome to Exagen Inc fourth quarter 2024 earnings conference call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Ryan Douglas, Investor Relations. Thank you, you may begin.
Good morning and thank you for joining us. Earlier today, Exagen Inc released financial results for the quarter and year-ended December 31, 2024. John Aballi, our President and Chief Executive Officer; and Jeff Black, our Chief Financial Officer, will host this morning's call. A recording of today's call and the press release announcing our results can be found on the company's website at www.exagen.com.
As today's call includes forward-looking statements, we encourage you to review the statements contained in today's press release and the risk and uncertainties described in our SEC filings, which identify certain factors that may cause the company's actual events, performance, and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
